BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE

(19)

(11)

EP 1 784 388 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	19.05.2010 Bulletin 2010/20

(45)	Mention of the grant of the patent:
	04.11.2009 Bulletin 2009/45

(21)	Application number: 05773308.1

(22)	Date of filing: 22.08.2005

(51)

International Patent Classification (IPC):

C07C 317/22^(2006.01)
C07D 295/18^(2006.01)
C07D 211/16^(2006.01)
C07D 261/02^(2006.01)
C07D 207/10^(2006.01)
A61P 11/00^(2006.01)

C07D 295/26^(2006.01)
C07D 205/04^(2006.01)
C07D 207/06^(2006.01)
C07C 235/42^(2006.01)
A61K 31/192^(2006.01)

(86)	International application number:
	PCT/GB2005/003255

(87)	International publication number:
	WO 2006/021759 (02.03.2006 Gazette 2006/09)

(54)	BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE BIPHENYLOXYESSIGSÄURE - DERIVATE ZUR BEHANDLUNG VON ATEMWEGSERKRÄNKUNGEN DERIVÉS D'ACIDE BIPHÉNYLOXYACÉTIQUE POUR LE TRAITEMENT DE LA MALADIE RESPIRATOIRE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
	Designated Extension States:
	AL BA HR MK YU

(30)

Priority:

24.08.2004 GB 0418830

(43)	Date of publication of application:
	16.05.2007 Bulletin 2007/20

(73)	Proprietor: AstraZeneca AB
	151 85 Södertälje (SE)

(72)	Inventors:
	LUKER, Timothy, Jon, AstraZeneca R&D Charnwood Loughborough, Leicestershire LE11 5RH (GB) BIRKINSHAW, Timothy , Nicholas Loughborough, Leicestershire LE11 5RH (GB) MOHAMMED, Rukhsana, Tasneem Loughborough, Leicestershire LE11 5RH (GB)

(74)	Representative: Summersell, Richard John
	AstraZeneca AB, Global Intellectual Property 151 85 Södertälje 151 85 Södertälje (SE)

(56)

References cited: :

EP-A- 1 170 594
WO-A-2004/089885

WO-A-99/11605
US-A- 5 006 542

H.-J. LEHMLER, ET AL.: "Synthesis of hydroxylated PCB metabolites with the Suzuki coupling" CHEMOSPHERE, vol. 45, no. 8, December 2001 (2001-12), pages 1119-1127, XP002350952 ELSEVIER SCIENCE, OXFORD, GB ISSN: 0045-6535

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).